Polymyxin B for Injection, USP
 
Brand Name / Company

Polymyxin B for Injection

Bedford Laboratories™

本品为硫酸多粘菌素B的无菌粉末。按干燥品计算，每1mg的效价不得少于6500多粘菌素B单位；按平均装量计算，含多粘菌素B应为标示量的90.0%~110.0%。
【性状】 本品为白色或类白色粉末。
【药品名称】
通用名：注射用硫酸多粘菌素B英文名：Polymyxini B Sulphas for Injection
汉语拼音：Zhusheyong Liusuan DuonianjunsuB
剂型：注射剂(冻干粉)
【成分】本品为硫酸多粘菌素B的无菌粉末。
化学名称：化学结构式：分子式：分子量：
【适应症】主要应用于绿脓杆菌及其它假单胞菌引起的创面、尿路以及眼、耳、气管等部位感染，也可用于败血症、腹膜炎。
【用法用量】
1.静滴：成人及儿童肾功能正常者1日每千克体重1.5～2.5mg（一般每千克体重不超过2.5mg），分成2次，每12小时滴注1次。每50mg本品，以5％葡萄糖液5００ｍｌ稀释后滴入。婴儿肾功能正常者每千克体重可耐受1日4mg的用量。
2.肌注：成人及儿童：1日每千克体重2.5～3mg，分次给予，每4～6小时用药1次。婴儿1日量每千克体重可用到4mg，新生儿每千克体重可用到4.5mg。
3.鞘内注射（用于绿脓桿菌性脑膜炎）：以氯化钠注射液制备每毫升药液含5mg。成人与2岁以上儿童，每日5mg，应用3～4日后，改为隔日1次，至少2周，直至脑脊液培养阴性，检验糖量正常。2岁以下儿童，用2mg，每日1次，连续3～4日（或者2.5mg隔日1次），以后用2.5mg，隔日1次，直到检验正常。
4.滴眼液浓度每毫升1～2.5mg。
【不良反应】
1.对肾脏的损害较多见，肾功能不全者应减量。
2.静注可能招致呼吸抑制，一般不采用。
3.鞘内注射量1效不宜超过5mg，以防引起对脑膜或神经组织的刺激。
4.不应与其他有肾毒性或神经肌肉阻滞作用的药物联合应用，以免发生意外。
【禁忌】
【注意事项】
1.对肾脏的损害较多见，肾功能不全者应减量。
2.静注可能招致呼吸抑制，一般不采用。
3.鞘内注射量1效不宜超过5mg，以防引起对脑膜或神经组织的刺激。
4.不应与其他有肾毒性或神经肌肉阻滞作用的药物联合应用，以免发生意外。
【规格】50万单位
【贮藏】密闭，在干燥处保存。
【包装】安瓿瓶每盒10支

用于美容术用伤，中耳炎，骨髓炎外用效果好

Polymyxin b sulphate is one of a group of basic polypeptide antibiotics de-rived from bacillus polymyxa. Poly-mxb™ is in lyophilized cake form suitable for preparation of sterile solutions for intramuscular, intravenous drip, intrathecal or as subconjunctival injection only (see dose & administration section below).
Polymyxin B Inj
Generic Name for Polymyxin B Inj
Polymyxin B sulfate 500,000units/vial; pwd for IM, intrathecal inj, IV drip or ophthalmic use after reconstitution.
Legal Classification:
Rx
Pharmacological Class for Polymyxin B Inj
Antibiotic.
Manufacturer of Polymyxin B Inj
Various generic manufacturers
Indications for Polymyxin B Inj
Susceptible infections due to P. aeruginosa including UTIs, meninges, bloodstream, and eye infections. Other serious susceptible infections including H. influenza meningeal, E. coli UTIs, and bacteremia due to A. aerogenes and K. pneumoniae.
Adults and Children:
Infants: up to 40,000units/kg per day IV or IM inj. Adults and children: IV: 15,000–25,000units/kg per day in divided doses every 12 hours; max 25,000units/kg per day. IM: 25,000–30,000units/kg per day in divided doses every 4–6 hours. P. aeruginosa meningitis: Give by intrathecal inj only. <2yrs: 20,000units once daily for 3–4 days or 25,000units once every other day, continue with 25,000units once every other day; >2yrs: 50,000units once daily for 3–4 days, then 50,000units once every other day; both: treat for at least 2 weeks after negative CSF cultures and sugar content normalized. Ophthalmic: see literature. Renal impairment: adjust or reduce dose.
Warnings/Precautions for Polymyxin B Inj
Renal impairment. Monitor renal function before and during therapy; discontinue if nephrotoxicity occurs. Pregnancy: not recommended.
Interactions for Polymyxin B Inj
Avoid other neurotoxic and/or nephrotoxic drugs (eg, bacitracin, aminoglycosides, colistin). May potentiate neuromuscular blockade with anesthetics and/or muscle relaxants.
Adverse Reactions for Polymyxin B Inj
Nephrotoxicity (eg, albuminuria, azotemia, cylindruria), neurotoxicity (eg, flushing, dizziness, paresthesias), meningeal irritation (intrathecal), drug fever, rash, inj site pain, thrombophlebitis; respiratory paralysis (discontinue if occurs).
Generic Name for Polymyxin B Inj
Polymyxin B sulfate 500,000units/vial; pwd for IM, intrathecal inj, IV drip or ophthalmic use after reconstitution.

Legal Classification:
Rx
Pharmacological Class for Polymyxin B Inj
Antibiotic.

Manufacturer of Polymyxin B Inj
Various generic manufacturers

Indications for Polymyxin B Inj
Susceptible infections due to P. aeruginosa including UTIs, meninges, bloodstream, and eye infections. Other serious susceptible infections including H. influenza meningeal, E. coli UTIs, and bacteremia due to A. aerogenes and K. pneumoniae.

Adults and Children:
Infants: up to 40,000units/kg per day IV or IM inj. Adults and children: IV: 15,000–25,000units/kg per day in divided doses every 12 hours; max 25,000units/kg per day. IM: 25,000–30,000units/kg per day in divided doses every 4–6 hours. P. aeruginosa meningitis: Give by intrathecal inj only. <2yrs: 20,000units once daily for 3–4 days or 25,000units once every other day, continue with 25,000units once every other day; >2yrs: 50,000units once daily for 3–4 days, then 50,000units once every other day; both: treat for at least 2 weeks after negative CSF cultures and sugar content normalized. Ophthalmic: see literature. Renal impairment: adjust or reduce dose.
Warnings/Precautions for Polymyxin B Inj
Renal impairment. Monitor renal function before and during therapy; discontinue if nephrotoxicity occurs. Pregnancy: not recommended.
Interactions for Polymyxin B Inj
Avoid other neurotoxic and/or nephrotoxic drugs (eg, bacitracin, aminoglycosides, colistin). May potentiate neuromuscular blockade with anesthetics and/or muscle relaxants
Adverse Reactions for Polymyxin B Inj
Nephrotoxicity (eg, albuminuria, azotemia, cylindruria), neurotoxicity (eg, flushing, dizziness, paresthesias), meningeal irritation (intrathecal), drug fever, rash, inj site pain, thrombophlebitis; respiratory paralysis (discontinue if occurs).

How is Polymyxin B Inj supplied?
Contact supplier.

Related Disease:
Infections, bacterial~systemic antiinfectives

Polymyxin B Sulfate Powder 0.5MU Pfizer (500000単位)

Polymyxin B Sulfate Powder 3MU Pfizer (300万単位)